Development and evaluation of a fluorescence microplate assay for quantification of heparins and other sulfated carbohydrates

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 1, 2010, Pages 1-8

  Lühn, Susanne ^a   Schrader, Thomas ^b   Sun, Wei ^b   Alban, Susanne ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Assay; Glucan sulfate; Glycosaminoglycan; Heparin; OSCS; Quantification

Indexed keywords

CARBOHYDRATE DERIVATIVE; CERTOPARIN; CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; DERMATAN SULFATE; DEXTRAN SULFATE; ENOXAPARIN; FLUORESCENT DYE; FONDAPARINUX; GLUCAN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; HYA JECT; HYALURONIC ACID; LAMINARAN; MONOEMBOLEX; NADROPARIN; POLYMER; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CALIBRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; FLUORESCENCE ANALYSIS; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHILICITY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; SULFATION;

CALIBRATION; EQUIPMENT DESIGN; FLUORESCENCE; FLUORESCENT DYES; GLYCOSAMINOGLYCANS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HYDROGEN-ION CONCENTRATION; MICROCHEMISTRY; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; OSMOLAR CONCENTRATION; POLYSACCHARIDES; REPRODUCIBILITY OF RESULTS; SODIUM CHLORIDE; SPECTROMETRY, FLUORESCENCE; TEMPERATURE; TIME FACTORS;

EID: 74249098244     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.12.014     Document Type: Article

References (39)

1. Hirsh J., Guyatt G., Albers G.W., Harrington R., and Schunemann H.J. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 71S-109S
2. Bianchini P., Liverani L., Spelta F., Mascellani G., and Parma B. Variability of heparins and heterogeneity of low molecular weight heparins. Semin. Thromb. Hemost. 33 (2007) 496-502
3. Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr. Pharm. Des. 14 (2008) 1152-1175
4. Alban S. Pharmacology of heparins and direct anticoagulants. Hamostaseologie 28 (2008) 400-420
5. Björk I., Olson S.T., and Shore J.D. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In: Lane D.A., and Lindahl U. (Eds). Heparin, Chemical and Biological Properties, Clinical Applications (1989), Boca Raton, CRC Press, Florida 229-256
6. Beguin S., Welzel D., Al Dieri R., and Hemker H.C. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 29 (1999) 170-178
7. Smorenburg S.M., and Van Noorden C.J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 53 (2001) 93-105
8. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 114 (2006) 79-102
9. Ludwig R.J., Alban S., and Boehncke W.H. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev. Med. Chem. 6 (2006) 1009-1023
10. Alban S. Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles. Hamostaseologie 28 (2008) 51-61
11. Ludwig R.J., Alban S., Bistrian R., Boehncke W.H., Kaufmann R., Henschler R., and Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb. Haemost. 95 (2006) 535-540
12. Simonis D., Fritzsche J., Alban S., and Bendas G. Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition. Biochemistry 46 (2007) 6156-6164
13. Stevenson J.L., Choi S.H., and Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. 11 (2005) 7003-7011
14. Summary of Workshop Sessions, 2nd Workshop on the characterisation of heparin products, Symposium organized by the European Directorate for the Quality of Medicines & HealthCare (Council of Europe), United States Pharmacopoeia and the National Institute for Biological Standards & Control, Available at: http://www.edqm.eu/medias/fichiers/Summary_of_Workshop_Sessions.pdf, Accessed September 10, 2009.
15. Blumenkrantz N., and Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal. Biochem. 54 (1973) 484-489
16. Kuettner K.E., and Lindenbaum A. Analysis of mucopolysaccharides in partially aqueous media. Biochim. Biophys. Acta 101 (1965) 223-225
17. Casu B., and Gennaro U. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr. Res. 39 (1975) 168-176
18. Volpi N., and Maccari F. Electrophoretic approaches to the analysis of complex polysaccharides. J. Chromatogr. 834 (2006) 1-13
19. Ma S.C., Yang V.C., and Meyerhoff M.E. Heparin-responsive electrochemical sensor: a preliminary study. Anal. Chem. 64 (1992) 694-697
20. N.N. Manual of the Blyscan™ glycosaminoglycan assay, Available at: http://www.biocolor.co.uk/blyscan.html, Accessed September 10, 2009.
21. Briza T., Kejik Z., Cisarova I., Kralova J., Martasek P., and Kral V. Optical sensing of sulfate by polymethinium salt receptors: colorimetric sensor for heparin. Chem. Commun. (Camb.) 16 (2008) 1901-1903
22. Sauceda J.C., Duke R.M., and Nitz M. Designing fluorescent sensors of heparin. Chembiochem 8 (2007) 391-394
23. Wang S., and Chang Y.T. Discovery of heparin chemosensors through diversity oriented fluorescence library approach. Chem. Commun. (Camb.) 10 (2008) 1173-1175
24. Wang M., Zhang D., Zhang G., and Zhu D. The convenient fluorescence turn-on detection of heparin with a silole derivative featuring an ammonium group. Chem. Commun. (Camb.) 37 (2008) 4469-4471
25. Wright A.T., Zhong Z., and Anslyn E.V. A functional assay for heparin in serum using a designed synthetic receptor. Angew. Chem. Int. Ed. Engl. 44 (2005) 5679-5682
26. Koch S.J., Renner C., Xie X., and Schrader T. Tuning linear copolymers into protein-specific hosts. Angew. Chem. Int. Ed. Engl. 45 (2006) 6352-6355
27. Sun W., Bandmann H., and Schrader T. A fluorescent polymeric heparin sensor. Chemistry 13 (2007) 7701-7707
28. Alban S., Welzel D., and Hemker H.C. Pharmacokinetic and pharmacodynamic characterisation of a medium-molecular-weight heparin in comparison with UFH and LMWH. Semin. Thromb. Hemost. 28 (2002) 369-378
29. Baumann H., Scheen H., Huppertz B., and Keller R. Novel regio- and stereoselective O-6-desulfation of the glucosamine moiety of heparin with N-methylpyrrolidinone-water or N,N-dimethylformamide-water mixtures. Carbohydr. Res. 308 (1998) 381-388
30. Maruyama T., Toida T., Imanari T., Yu G., and Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 306 (1998) 35-43
31. Becker M., Franz G., and Alban S. Inhibition of PMN-elastase activity by semisynthetic glucan sulfates. Thromb. Haemost. 89 (2003) 915-925
32. Alban S., and Franz G. Partial synthetic glucan sulfates as potential new antithrombotics: a review. Biomacromolecules 2 (2001) 354-361
33. Alban S., and Franz G. Gas-liquid chromatography-mass spectrometry analysis of anticoagulant active curdlan sulfates. Semin. Thromb. Hemost. 20 (1994) 152-158
34. McFarland S.A., and Finney N.S. Fluorescent chemosensors based on conformational restriction of a biaryl fluorophore. J. Am. Chem. Soc. 123 (2001) 1260-1261
35. Ni W., Kaur G., Springsteen G., Wang B., and Franzen S. Regulating the fluorescence intensity of an anthracene boronic acid system: a B-N bond or a hydrolysis mechanism?. Bioorg. Chem. 32 (2004) 571-581
36. ICH harmonized tripartite guideline, Validation of analytical procedures: text and methodology Q2 (R1) Current Step 4 version 2005, Available at: http://www.ich.org/cache/compo/363-272-1.html, Accessed September 10, 2009.
37. S. Alban, S. Lühn, S. Schiemann, Verfahren zur Bestimmung der Qualität von Heparin, PCT application, PCT/DE 2009/001215, 03.09.09.
38. N.N. Heparin Sodium, Ph. Eur. 6.1, 2009: Monograph: 0333.
39. N.N. Heparin Sodium, Stage 2 Monograph, The United States Pharmacopeial Convention, Pharmacopeial Forum Vol. 35, September-October 2009.